8-K: Edgewell Sells Feminine Care Business for $340M

Sentiment:

Asset Sale Announcement 13 November 2025 6:03 AM

📋All filings for Edgewell Personal Care CO

Edgewell Personal Care Company announced a definitive agreement to sell its Feminine Care business, including Playtex, Stayfree, Carefree, and o.b. brands, to Essity for $340 million in cash.

Delay expectedThe initial Outside Date for transaction completion is May 12, 2026.This date can be automatically extended to August 12, 2026, if required regulatory approvals remain outstanding.A further automatic extension to November 12, 2026, is possible if regulatory approvals are still outstanding.The Outside Date can also be extended by up to five Business Days if the last conditions are met less than five Business Days prior to the Outside Date.

Summary

Edgewell Personal Care Company (EPC) entered into a definitive Asset Purchase Agreement to sell its Feminine Care segment (the Business) to Essity Aktiebolag (publ) for $340 million in cash.
The Business comprises the design, development, manufacturing, marketing, promotion, selling, and distribution of feminine care products, including the Playtex, Stayfree, Carefree, and o.b. brands.
The transaction is subject to customary closing conditions, including the receipt of required regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
Edgewell intends to use the net proceeds from the sale, after taxes and transaction costs, primarily to strengthen its balance sheet and invest in the long-term growth of its core businesses.
The transaction is expected to close in the first quarter of calendar 2026.
Beginning in the first quarter of fiscal 2026, Edgewell will classify the Feminine Care business as discontinued operations.
Edgewell expects the annualized impact of the sale to be approximately $0.40 to $0.50 cents in adjusted EPS and $35 to $45 million in adjusted EBITDA, net of income generated from transition support services to Essity.

Sentiment

Score: 7

Explanation: The transaction is strategically positive for Edgewell, allowing portfolio streamlining and balance sheet strengthening. While there are risks associated with any divestiture and integration, the stated benefits and clear path forward suggest a generally positive outlook for the company's future direction.

Positives

The transaction streamlines Edgewell's portfolio, allowing the company to sharpen its focus on core categories and areas of competitive leadership.
The sale is expected to strengthen Edgewell's financial position and balance sheet.
The divestiture positions Edgewell for sustainable, long-term growth by enabling investment in core businesses.
Shareholders are expected to benefit from a more agile and focused company.
Customers of the Feminine Care business are expected to continue receiving innovative products and dedicated service under Essity's ownership.
Employees of the Feminine Care business will have new opportunities for growth and success with Essity, a global leader in health and hygiene.

Negatives

Edgewell expects to incur certain stranded overhead costs following the transaction.
However, these stranded overhead costs for fiscal 2026 are expected to be substantially offset by income generated from the provision of transition support services to Essity.

Risks

Risk that the parties may be unable to close the transaction on anticipated timelines or at all.
Failure to obtain required regulatory approvals or satisfy other conditions to closing.
Costs associated with the transaction and the potential that it may not have the anticipated impact on the company's business.
Risk that disruptions from the transaction will harm business plans and operations.
Ability to compete in products and prices, as well as costs, in an intensely competitive industry.
Loss of any principal customers or changes in the policies of principal customers.
Inability to design and execute a successful omnichannel strategy.
Ability to attract, retain, and develop key personnel.
Fluctuations in the price and supply of raw materials and costs of labor, warehousing, and transportation.

Future Outlook

Edgewell anticipates the transaction will close in the first quarter of calendar 2026, allowing the company to sharpen its focus on core categories, strengthen its financial position, and pursue sustainable, long-term growth. The company expects to classify the Feminine Care business as discontinued operations from Q1 fiscal 2026 and projects an annualized impact of approximately $0.40 to $0.50 cents in adjusted EPS and $35 to $45 million in adjusted EBITDA, net of transition service income. Edgewell will also provide transition services to Essity post-closing.

Management Comments

"This transaction marks a pivotal step in Edgewell’s transformation. By selling our Feminine Care business to Essity, we are sharpening our focus on our core categories, strengthening our financial position, and positioning Edgewell for sustainable, long-term growth." Rod Little, President and CEO of Edgewell.
"This is a win for our shareholders who will benefit from a more agile and focused company; for our customers, who will continue to receive innovative products and dedicated service; and for our employees, who will have new opportunities for growth and success with Essity, a global leader in health and hygiene." Rod Little, President and CEO of Edgewell.
"I’m excited to further grow these well-known brands by welcoming them into our bold and purpose-driven feminine care business. With this acquisition we are building a stronger personal care business in North America, in line with our strategy to focus on high yielding categories in attractive geographies." Ulrika Kolsrud, President and CEO of Essity.

Industry Context

Essity is described as a global, leading hygiene and health company, and this acquisition aligns with their strategy to focus on high-yielding categories in attractive geographies, particularly strengthening their personal care business in North America. For Edgewell, the divestiture allows them to streamline their portfolio and focus on areas of competitive leadership within the broader consumer products industry.

Comparison to Industry Standards

The provided content does not offer specific comparable companies, projects, or results to assess the transaction in the context of global benchmarks.
Essity is identified as a 'global leader in health and hygiene,' and the acquisition is stated to be 'in line with our strategy to focus on high yielding categories in attractive geographies,' implying a strategic fit within industry trends for the buyer.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director and Officer of Acquired Seller Party (Playtex Marketing Corporation)	Employees of Seller or a Seller Affiliate	Designated by Buyer	Upon Closing	Resignations to be delivered by Seller, effective upon Closing, to facilitate Buyer's control of the acquired entity.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board and Officer Composition Change	Resignations of current directors and officers of the Acquired Seller Party (Playtex Marketing Corporation) who are employees of Seller or a Seller Affiliate, effective upon Closing. Buyer will designate new directors and officers.	Upon Closing	Ensures Buyer gains full control and governance of the acquired entity immediately post-closing.
Ratification of Past Actions	Joint written consent signed by all directors and stockholders of the Acquired Seller Party affirming names of current directors/officers and ratifying all actions taken on behalf of the Acquired Seller Party prior to the Closing Date.	Prior to Closing	Provides legal certainty and validation for pre-closing corporate actions under the previous ownership.
Release of Fiduciary Duty Claims	Seller to cause delivery of a release of claims with respect to a breach of fiduciary duty by each owner of Equity Interests of the Acquired Seller Party, releasing claims against the Acquired Seller Party arising prior to the Closing.	Prior to Closing	Protects the Acquired Seller Party from potential fiduciary duty claims related to pre-closing activities by its previous owners.

Legal Proceedings

None explicitly detailed in the provided filing content, beyond general risks mentioned in forward-looking statements. The filing notes that, except as set forth in the Seller Disclosure Letter (which is not provided), there have been no judgments, pending or threatened proceedings, or investigations by any Governmental Entity relating primarily to the Business or Acquired Assets since January 1, 2021.

Related Party Transactions

Effective as of the Closing, all Contracts between Seller or its Affiliates (on one hand) and the Acquired Seller Party (on the other hand) will be terminated, with certain exceptions for Transaction Documents and contracts necessary to permit Seller to perform its obligations under the Transition Services Agreement.
Seller grants Buyer a non-exclusive, perpetual, irrevocable, royalty-free, transferable license, with the right of sublicense, to all Know-How Rights owned by Seller or any Seller Party (other than the Acquired Seller Party) as of the Closing that were used or held for use in the Business prior to the Closing (but are not Acquired Assets) for use by Buyer in the operation and conduct of the Business after the Closing.
Buyer grants Seller and its Affiliates a non-exclusive, perpetual, irrevocable, royalty-free, transferable license, with the right of sublicense, to all Know-How Rights that are Acquired Assets and that were used or held for use in the Retained Businesses prior to Closing for use by Seller and Seller Affiliates exclusively in the operation and conduct of the Retained Business after the Closing.

Stakeholder Impact

**Shareholders**: Expected to benefit from a more agile and focused company, strengthened balance sheet, and sustainable long-term growth due to the strategic divestiture.
**Employees (Feminine Care Business)**: Will transition to Essity, a global leader in health and hygiene, and are expected to have new opportunities for growth and success.
**Customers (Feminine Care Business)**: Expected to continue receiving innovative products and dedicated service from Essity.
**Edgewell Employees (Remaining Business)**: The company's strategic focus and investment in core businesses could lead to enhanced opportunities and stability within the remaining segments.

Next Steps

Satisfy customary closing conditions, including receipt of required regulatory approvals (HSR Act).
Edgewell will work closely with Essity to ensure a smooth transition for employees, customers, and consumers of the Feminine Care business.
Edgewell has agreed to provide Essity with certain services to support the transition of the business following the completion of the transaction.
Edgewell will update its FDA registration and medical device listing and Health Canada medical device licenses to de-list as the manufacturer or distributor of Business Products.
Buyer will update its FDA establishment registration and medical device listing and Health Canada medical device licenses to list Buyer as the manufacturer or distributor of the Business Products.
An Integration Committee will coordinate and facilitate the completion of all actions, consents, deliveries, and other matters required between the signing date and the Closing.

Key Dates

Date	Description
January 29, 2025	Date of the Confidentiality Agreement between Buyer and Seller.
March 31, 2025	End of the six-month period for which unaudited inventory, net fixed assets balances, and related income statement for the Business were provided.
September 30, 2023	Fiscal year end for which unaudited income statement for the Business was provided.
September 30, 2024	Fiscal year end for which unaudited income statement for the Business was provided, and the year for which the Annual Report on Form 10-K is referenced.
September 30, 2025	End of the 12-month period used for identifying largest customers, distributors, resellers, suppliers, contract manufacturers, or vendors.
November 12, 2025	Date of report (earliest event reported), Signing Date of the Asset Purchase Agreement, and date of the press release announcing the transaction.
November 13, 2025	Date the Current Report on Form 8-K was signed by Francesca Weissman, Chief Financial Officer.
First quarter of calendar 2026	Expected closing timeline for the transaction.
First quarter of fiscal 2026	Beginning of the period when Edgewell will classify the Feminine Care business as discontinued operations.
February 2, 2026	Latest possible delayed Closing Date if Buyer elects to delay the Closing from the Original Date.
May 12, 2026	Initial Outside Date for transaction completion.
August 12, 2026	First automatic extension of the Outside Date if certain required regulatory approvals remain outstanding.
November 12, 2026	Second automatic extension of the Outside Date if certain required regulatory approvals remain outstanding.

Recommendation

hold

The divestiture of the Feminine Care business for $340 million is a significant strategic move for Edgewell, aimed at streamlining its portfolio and strengthening its balance sheet. While the transaction is expected to be accretive to focus and financial health, the immediate impact on the remaining business's performance and the effective deployment of proceeds will be key. Investors should hold to observe the execution of Edgewell's refined strategy and the financial results of its core businesses post-divestiture, as well as the actual impact of stranded costs and transition service income.

Keywords

Edgewell Personal Care, Essity, Feminine Care, Divestiture, Asset Sale, Playtex, Stayfree, Carefree, o.b., Consumer Products, Health and Hygiene, Portfolio Streamlining, Balance Sheet, Strategic Focus

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.